Systematic review and meta-analysis of intravenous iron therapy for adults with non-anaemic iron deficiency: An abridged Cochrane review

Cory Dugan1*, Katerina Cabolis2, Lachlan F. Miles3 & Toby Richards1,2

1Division of Surgery, Faculty of Health and Medical Science, The University of Western Australia, Perth, Australia; 2Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK; 3Department of Critical Care, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia

Abstract

Iron is an essential nutrient for oxygen supply and aerobic metabolism. Iron deficiency impacts cellular respiration and mitochondrial energy metabolism, which can lead to reduced skeletal muscle function and muscle mass, causing sarcopenia. Intravenous iron offers the ability to rapidly correct iron deficiency, but the functional impact on patient mental and physical health is unclear. We assessed the effects of intravenous iron therapy on physical function and quality of life in the treatment of adults with non-anaemic iron deficiency. An update and reanalysis of a previously published Cochrane systematic review was performed to assess randomized controlled trials that compared any intravenous iron preparation with placebo in adults. The primary functional outcome measure was physical performance as defined by the trial authors. Secondary outcome measures included fatigue and quality-of-life scores, and adverse events at the end of follow-up. Biochemical efficacy was assessed by change in serum ferritin and haemoglobin concentration levels. Twenty-one randomized controlled trials, comprising 3514 participants, were included. Intravenous iron compared with placebo resulted in significantly increased physical function measured by mean peak oxygen consumption (mean difference [MD] 1.77 mL/kg/min, 95% confidence interval [CI] 0.57 to 2.97). An overall improvement in fatigue was seen (standardized MD 0.30, 95% CI −0.52 to −0.09) but no overall difference in quality of life (MD 0.15, 95% CI −0.01 to 0.31). Biochemically, intravenous iron resulted in improved serum ferritin (MD 245.52 μg/L, 95% CI 152.1 to 338.9) and haemoglobin levels (MD 4.65 g/L, 95% CI 2.53 to 6.78). There was a higher risk of developing mild adverse events in the intravenous iron group compared with the placebo group (risk ratio 1.77, 95% CI 1.10 to 2.83); however, no differences were seen in serious adverse events (risk difference 0, 95% CI −0.01 to 0.01). The quality of evidence was rated ‘low’ and ‘very low’ for all outcome variables, except for fatigue, mainly due to most studies being judged as having a high risk of bias. In non-anaemic iron-deficient adults, the use of intravenous iron compared with placebo improved physical function and reduced fatigue scores. However, we remain uncertain about the efficacy in this population due to low-quality evidence, and there is a need for further studies to address potential impact on overall quality of life.

Keywords anaemia; physical function; fatigue; iron deficiency; sarcopenia

Received: 26 May 2022; Revised: 4 September 2022; Accepted: 21 September 2022
*Correspondence to: Cory Dugan, School of Human Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia.
Email: cory.dugan@research.uwa.edu.au

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

Iron deficiency is the most common nutritional deficiency and cause of anaemia worldwide. The World Health Organization (WHO) regards iron deficiency anaemia as a key contributor to disability, with negative associations on exercise tolerance and mental well-being. However, the impact of iron deficiency without anaemia on physical function is less well defined.

Iron is a fundamental micronutrient essential for the transport and storage of oxygen, as well as mitochondrial energy production, which generates adenosine triphosphate (ATP) through aerobic respiration (oxidative phosphorylation) in the electron transport chain. This is particularly relevant for skeletal muscle, which contains up to 10–15% of total body iron and requires adequate levels of iron to support healthy mass and function. Iron deficiency can reduce the cellular ability for aerobic respiration, leading to compromised ATP production, which, in turn, is associated with a decrease in aerobic capacity and muscle function (Figure 1). These aetiological processes have implicated iron deficiency as a contributing factor for the development, and recovery, from sarcopenia.

Intravenous iron has become an established treatment option to rapidly replenish iron stores and effective treat iron deficiency anaemia. However, the evidence supporting the use of intravenous iron in non-anaemic iron-deficient adults, specifically the impact on physical function and performance, is equivocal, with clinical trials reporting both increases and no change to exercise capacity. In a recent Cochrane review, low-quality evidence in the included studies reporting maximum oxygen consumption (VO2 max) and quality-of-life measures meant that appropriate analysis could not be conducted accurately. This was in the most part due to heterogeneity in research protocols that included different participant populations, with variation in the definition of iron deficiency, and used different doses of iron or different modalities of inconsistent administration. When focusing solely on women populations of reproductive age, previous

![Diagram depicting the energetic pathway of skeletal muscle tissue](image)

**Figure 1** Diagram depicting the energetic pathway of skeletal muscle tissue (A) in a state of sufficient iron stores and (B) in a state of iron deficiency; there is a decrease in glycogen stores, an increase in lactate production, a decline in the Krebs cycle and oxidative phosphorylation and thereby lower levels of ATP overall. Oxidative phosphorylation panel highlights the role of iron in the electron transport chain. ADP, adenosine diphosphate; ATP, adenosine triphosphate; C, cytochrome c; e, electrons; ETC, electron transport chain; Fe2+, ferrous iron; Fe3+, ferric iron; H, hydrogen; H2O, water; I–IV, mitochondrial complexes I–IV; NEFA, non-esterified fatty acids; O2, oxygen; OXPHOS, oxidative phosphorylation; P, phosphate; Q, coenzyme Q.
meta-analysis has demonstrated improvements in maximal and submaximal physical function following iron supplementation. However, this review did not investigate parenteral iron therapies. Hence, the effect of intravenous iron therapy on physical function in non-anaemic iron-deficient individuals remains unresolved. Despite this, the use of intravenous iron continues to increase in developed countries, with multiple ‘best practice’, consensus statements and guidelines advocating for its use. The aforementioned lack of empirical evidence is particularly detrimental to women’s health, given that women are more likely to have iron deficiency compared with men when adopting equal reference ranges. Consequently, the current standard of care for women with iron deficiency has been called into question, with evidence suggesting the need to single women out and investigate further, rather than accept the dogma of normality.

To better understand the evidence driving recommendations and clinician behaviours, we assessed the effects of intravenous iron therapy in adults with non-anaemic iron deficiency by renewing and reanalysing the results of a previous Cochrane review with primary focus on the effect of intravenous iron on physical function and quality of life.

**Methods**

The Cochrane methodology was applied to this review. Table 1 presents the inclusion and exclusion criteria against which studies were screened.

| Inclusion criteria                                      | Exclusion criteria                                                   |
|--------------------------------------------------------|-----------------------------------------------------------------------|
| Study type                                             | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Publication Participants                               | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Intervention, comparisons                             | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Outcome measures                                       | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Randomized control trials (irrespective of blinding,   | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| language, study setting or sample size)                | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Trials were included irrespective of publication status| Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| and date of publication                                | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Any non-pregnant and non-lactating adults with         | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| functional or absolute iron deficiency, without       | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| anaemia. No anaemia defined as Hb > 130 g/L for men     | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| and Hb > 120 g/L for women.                            | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Any formulation of intravenous iron versus placebo.    | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Primary: Any measure of physical/muscle function,      | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| defined by the trial authors (e.g., VO₂ max, 6MWT and   | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| muscle function).                                      | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| Secondary: Haemoglobin concentration, measured at the   | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| end of follow-up; serum ferritin, measured at the end  | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| of follow-up; fatigue scores, measured using           | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| quantitative measurement scales taken at the end of     | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| follow-up; overall quality of life, measured using a    | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| quantitative measurement scale taken at the end of     | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| follow-up; risk of serious adverse events at end of    | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| follow-up, defined as any events that would increase    | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| mortality, were life threatening, required              | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| inpatient hospitalization or resulted in persistent or  | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| significant disability, or any medical events           | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| that might jeopardize the participants at the required  | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| intervention to prevent them within 30 days of cessation| Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| of treatment; and risk of mild adverse events at the    | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| end of follow-up, defined as any events that did not    | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| meet the definition of a serious adverse event but that | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| required treatment or resulted in patient discomfort;   | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| hypophosphataemia of any severity was included in this  | Quasi-randomized trials, cross-over trials, non-RCT designs.         |
| category.                                              | Quasi-randomized trials, cross-over trials, non-RCT designs.         |

Exclusion criteria:

| Exclusion criteria                                      |
|--------------------------------------------------------|
| Study type                                             |
| Types of participants                                  |
| Oral iron preparations                                 |

Abbreviations: 6MWT, 6-min walk test; Hb, haemoglobin; RCT, randomized controlled trial.
was not truly random (i.e., allocation based on medical record number, date of birth and day of week). Cluster-randomized trials were considered for inclusion if the method of randomization was truly random (i.e., random number sequence and coin flip). Finally, cross-over trials were excluded as it is considered an inappropriate design to assess this intervention.

All adults (18 years and above) with functional or absolute non-anaemic iron deficiency were included. Non-anaemic iron deficiency was defined as having a haemoglobin concentration > 130 g/L for men and >120 g/L for non-pregnant women. Studies that did not differentiate haemoglobin concentration levels between men and women and set a non-anaemic definition of >120 g/L for both sexes were also included. In order to capture the broadest possible population, a series of RCTs from the existing literature was reviewed to define iron deficiency and chose the least restrictive definition. Iron deficiency was defined as follows:

1. absolute: ferritin < 100 μg/L; and
2. functional: ferritin more than 100 μg/L and transferrin saturation (TSAT) < 20%.

**Assessment of the risk of bias**

Included studies were assessed for risk of bias according to the criteria outlined in tab. 8.5.d in the Cochrane Handbook for Systematic Reviews of Interventions. The domains used to assess the risk of bias were selection bias (random sequence generation and allocation concealment), blinding bias (blinding of participants and personnel and blinding of outcome assessment), attrition bias (amount, nature and handling of incomplete outcome data), reporting bias (selective reporting of outcome data) and other bias (bias not covered elsewhere such as source of funding bias). Two review authors (CD and KC) identified studies for inclusion independently of each other. Disagreements were resolved through discussion or, if required, through involvement of a third review author (LFM).

**Statistical analysis**

Meta-analyses were performed using the software package Review Manager Version 5.3 and in accordance with the recommendations of the Cochrane handbook. All effect estimates were calculated using a random effects model. Different treatment effects were used depending on the type of data. For continuous outcomes, using the inverse variance method, the mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CIs) were calculated where appropriate.

All SMD calculations were re-expressed in units of the commonest scale in accordance with guidance from the Cochrane handbook. As several trials used different scales to assess physical function (6-min walk test, fibromyalgia impact questionnaire [FIQR] walk score, short form [SF12] physical score and peak oxygen consumption) at different time points, and due to the lack of response from relevant authors for data, an analysis was conducted on all physical function outcomes irrespective of units or scale. This was achieved by calculating the SMD of each variable with respect to the change from baseline, which was re-expressed back into peak oxygen consumption (mL/kg/min) using a typical SD from the included studies, in accordance with the Cochrane handbook.

Several trials also used a variety of scales to measure fatigue scores (Piper fatigue score, visualnumeric scale [VNS], numeric rating scale [NRS], multidimensional fatigue symptom inventory [MFSI], brief fatigue inventory [BFI] and fatigue severity scale [FSS]). Consequently, SMD was calculated and re-expressed back into the Piper Fatigue Scale using a typical SD from the included studies. For similar reasons, SMD was calculated for the quality-of-life measurements (EQ-5D, Kidney Disease Quality of Life [KDQoL] instrument, Minnesota Living with Heart Failure Questionnaire [MLFHQ], SF12 mental score, International Restless Legs Scale [IRLS], Kansas City Cardiomyopathy Questionnaire [KCCQ] and chronic obstructive pulmonary disease [COPD]), which was then re-expressed back into the EQ-5D, using a typical SD from the included studies.

For dichotomous outcomes, the Mantel–Haenszel technique was used. The risk ratio (RR) and 95% CIs were calculated for binary variables, except for serious adverse events, which involved the calculation of risk difference (RD) along with the 95% CIs.

Due to the lack of common protocols used in the research studies, a certain amount of heterogeneity was expected in the analysis. This was related to a number of factors, including marked differences in study population (ranging from athletes to individuals with heart failure) and the differing preparations and dosages of iron between studies. Consequently, the chi-squared ($\chi^2$) test was employed to explore heterogeneity of included studies with a significant alpha level of 0.05 determined a priori. We also measured heterogeneity using the $I^2$ statistic. Further, sensitivity analysis was conducted to assess the impact of varying definitions of iron deficiency on all outcomes. Specifically, studies that included patients with TSAT < 20% regardless of ferritin levels were excluded in this analysis, due to the possibility of varying iron deficiency aetiology (functional vs. absolute).

**Summary of findings and assessment of the certainty of the evidence**

The results of this review for all comparisons are displayed in a ‘Summary of findings’ table (Table 2). The primary outcome was MD in physical function (peak oxygen consumption: VO2

---

**Journal of Cachexia, Sarcopenia and Muscle** 2022; 13: 2637–2649
DOI: 10.1002/jcsm.13114
Results

Study selection

The conducted search yielded 3429 references. Following de-duplication and primary screening, 102 articles were selected for full-text screening, and 21 studies were included in the qualitative and quantitative analyses.18,19,23,33–35,38–52 Exclusions are detailed in Figure 2.
Study characteristics

The included studies reported results for 3514 participants. Of these studies, seven were in people with heart failure, three in people with restless legs syndrome, two in elite athletes, two in otherwise well, pre-menopausal women, two in people with fibromyalgia, and the remaining six were a variety of specific cohorts (following cardiac surgery, fibromyalgia, kidney disease, complex vascular heart surgery, COPD and cardiac transplant recipients). The most common placebo comparator used was sodium chloride (0.9%), and two studies were open-label interventions.

All studies were available through database searches as full manuscripts, with the exception of Wong et al., which was a conference extract. The risk of bias graph is illustrated in Figure 3, and a summary of the risk of bias analysis is presented in Figure 4. Further description of study characteristics can be found in Table 3.

Intervention

Studies used a variety of different intravenous iron group treatment regimens for the administration of the study drug. Twelve studies used a single-dose administration, whereas nine used repeat dosing at various points throughout the study. Ferric carboxymaltose was used in thirteen studies, ferric isomaltoside (ferric derisomaltose) was used in five studies, both preparations (ferric carboxymaltose and ferric derisomaltose) were used together in one study, and iron sucrose was used in two studies. The total dose of intravenous iron administered, where calculation was possible, ranged from 300 up to 2500 mg.

Physical function

Peak oxygen consumption

Four studies had endpoints that reported peak oxygen consumption measured at the end of follow-up (Figure 5A). Peak oxygen consumption taken at the end of follow-up in the intervention group was on average 1.77 mL/kg/min higher than that of placebo (95% CI 0.57 to 2.97; $I^2 = 0\%$; 4 studies, 194 participants; $P = 0.004$), but with ‘very low’ quality of evidence.

Physical function as defined by trial authors (standardized mean difference)

Seven studies, with a variety of assessments, reported physical function change relative to baseline scores (Figure 5B). Meta-analysis suggested that the mean physical function score was 0.68 SMD units higher in the intravenous iron group compared with that of placebo (95% CI 0.01 to 1.35; 7 studies, 639 participants; $P = 0.05$). Modelling the effect seen from the included studies (SD), this effect was re-expressed into mL/kg/min (peak oxygen consumption value). Overall, the effect of intravenous iron was an increase in peak oxygen consumption value by an MD of 1.76 mL/kg/min higher compared with placebo (95% CI 0.03 to 3.50). Considerable heterogeneity was present in this analysis ($I^2 = 92\%$; $\chi^2 = 75.47$, $P < 0.00001$), with ‘very low’ quality of evidence.

Fatigue at the end of follow-up

Five trials reported findings for fatigue at the end of follow-up, using a variety of scales (Figure 5C). Intravenous iron was associated with reduced fatigue. Meta-analysis suggested that the levels of fatigue taken at the end of follow-up were 0.30 SMD units lower in the intervention group (95% CI $-0.52$ to $-0.09$; $I^2 = 46\%$; 5 studies, 814 participants; $P = 0.006$). On average, the intravenous iron
group scored 0.61 lower in the Piper Fatigue Scale (95% CI −1.05 to −0.18), implying lower fatigue compared with placebo, with ‘moderate’ quality of evidence.

Quality of life at the end of follow-up

Eight trials included findings for quality of life using a variety of scales (Figure 5D). Overall, the effect of intravenous iron compared with placebo was not significant in terms of quality of life at the end of follow-up (SMD 0.15; 95% CI −0.01 to 0.31; I² = 26%; 8 studies, 1030 participants; P = 0.06). When re-expressing the results to generic quality-of-life scales (EQ-5D), a similar outcome was seen with improved scores in the intravenous iron group compared with placebo; however, this was not significant (MD 0.17; 95% CI −0.01 to 0.34 higher; P = 0.06), with ‘low’ overall quality of evidence.

Haemoglobin concentration

Fifteen studies reported haemoglobin concentration at the end of follow-up (Figure 6A). Intravenous iron resulted in a higher haemoglobin concentration relative to the placebo taken at the end of follow-up (MD 4.65 g/L; 95% CI 2.53 to 6.78; 15 studies, 1675 participants; P < 0.0001). Considerable heterogeneity was present in this analysis (I² = 81%; χ² = 73.61, P < 0.00001), with ‘low’ quality of evidence.

Ferritin concentration at the end of follow-up

Twelve studies reported ferritin concentration at the end of follow-up (Figure 6B). The MD in ferritin concentration taken at the end of follow-up was 245.52 μg/L higher in the intervention group relative to the placebo group (95% CI 152.11 to 338.94; 12 studies, 1242 participants; P < 0.00001). Considerable heterogeneity was present in this analysis (I² = 100%; χ² = 6703.94, P < 0.00001), with ‘very low’ quality of evidence.

Mild adverse events

Eleven trials included data corresponding to mild adverse events (Figure 6C). Intravenous iron resulted in a higher rate of mild adverse events relative to placebo (RR 1.77; 95% CI 1.10 to 2.83; 11 studies, 1412 participants; P = 0.02). Considerable heterogeneity was present in this analysis (I² = 91%; χ² = 113.91, P < 0.00001), with ‘low’ quality of evidence.

Serious adverse events

Eleven studies included data for serious adverse events (Figure 6D). No differences were seen between intravenous iron relative to placebo (RD 0; 95% CI −0.01 to 0.01; I² = 0%, 11 studies, 1182 participants; P = 0.99), with ‘low’ quality of evidence.

Sensitivity analysis

All relevant analyses were repeated with the exclusion of trials that included patients with TSAT < 20%, regardless of ferritin levels. No significant alterations were demonstrated in the results of all analyses.

Discussion

In this updated Cochrane systematic review, of 21 studies, with 3514 participants with non-anaemic iron deficiency, the use of intravenous iron compared with placebo resulted in improved physical function by recorded or modelled effect on peak oxygen consumption and reduced fatigue levels compared with placebo. However, no overall difference was seen in reported overall quality of life. The efficacy of intravenous iron compared with placebo in non-anaemic iron deficiency was associated with increased serum ferritin concentration and haemoglobin concentration.
The present review builds upon the previously conducted Cochrane review\(^2\) with the addition of new evidence of larger studies that allowed for improved quality evidence. Specifically, this enabled the determination of improved fatigue scores in response to intravenous iron treatment. To the best of our knowledge, this updated review is the first meta-analysis to confirm evidence of efficacy of intravenous iron for improved fatigue scores in non-anaemic iron-deficient adults. This is an important finding due to the significant increase in the use of intravenous iron globally in the last decade.\(^{25,26}\) Further, this finding is of particular significance to women’s health, where the current standard of care has been questioned and, subsequently, termed ‘misogynistic’.\(^{29}\) The improved quality evidence from the present review should better inform ‘best practice’, consensus statements and guidelines concerning the use of intravenous iron.

Impact of intravenous iron on muscle function and performance has demonstrated a mix of results, with studies reporting both increases\(^{22,24,53}\) and no change in exercise capacity in response to iron therapy.\(^{54-56}\) The divergence in findings have been explained, at least in part, by a recent prospective case control study, which demonstrated that although non-anaemic iron-deficient individuals treated with intravenous iron showed no differences in both aerobic respiration and VO\(_2\) max, intravenous iron increased lactate threshold during exercise, implying an increased ability to generate work aerobically with increasing exercise intensities in the absence of fatigue.\(^{57}\) These findings are in keeping with previous physiological experiments in animals with clinical implications.\(^{13}\) Further research investigating changes in lactate concentration in iron-deficient individuals treated with intravenous iron is needed to confirm this.

We acknowledge some limitations. Despite biological plausibility, and seemingly ‘positive’ results in some of the included trials, we were unable to reach robust conclusions as to the role of intravenous iron therapy in physical function in non-anaemic iron-deficient adults. This was primarily due to the often variable statistical and methodological heterogeneity. Several differences between studies regarding population demographics, as well as intravenous iron regime, dose and frequency, were evident, all of which likely contributed to the heterogeneity of results. Also, the definition of iron deficiency was highly variable across studies, including serum ferritin < 100, <50, <30 or <15 μg/L, with or without a TSAT < 20%, possibly further confounding the conclusions due to potentially differing iron deficiency aetiology (i.e., functional vs. absolute). Further to this, several studies were deemed to be high risk of bias. As a result, the overall quality of evidence for many of the outcomes was graded as either ‘low’ or ‘very low’, apart from fatigue scores, which were graded as ‘moderate’. This highlights the need to standardize trial endpoints with harmonized trial protocols as seen in the clinical literature.\(^{58}\) Finally, in addition to the aforementioned limitations, significant difficulties were encountered when
### Table 3. Summary of literature included in the meta-analysis

| Author(s)                | Participant cohort | Population | Definition of iron deficiency | Iron preparation | Dosing regimen | Total dose | Frequency | Follow-up |
|--------------------------|--------------------|------------|-------------------------------|------------------|----------------|------------|-----------|-----------|
| Bhanderi 2021            | n = 54 (n = 27 F)  | Kidney disease Ferritin < 100 or 100–200 μg/L | FCM 200 mg | Weekly until replete, then monthly | 1000 mg | Single dose | —         | 3 months |
| Boonershine 2018         | n = 80 F          | Fibromyalgia Ferritin < 50 μg/L and/or TSAT < 20% | Iron sucrose 20 mg | Two doses over 5 days | 20 mg/kg | Single dose | 1000 mg   | 10 days   |
| Bhandari 2021           | n = 549 (n = 244 F) | Heart failure Ferritin < 100 or 100–200 μg/L | FCM 1000 mg | Single dose | 1000 mg | 3 months | —         | 42 weeks |
| Brautset 2015            | n = 15 (n = 9 F)   | Chronic obstructive pulmonary disease Ferritin < 100 or 100–200 μg/L | FCM 608 ± 204 mg | Single dose | 608 ± 204 mg | 2 weeks | —         | —         |
| Charles-Edwards 2019    | n = 40 (n = 11 F)  | Cardiac transplant recipients Ferritin < 15 or < 30 μg/L | FCM 608 ± 204 mg | Single dose | 608 ± 204 mg | 2 weeks | —         | —         |
| Englund 2021             | n = 37 F          | Cardiac transplant recipients Ferritin < 15 or < 30 μg/L | FCM 608 ± 204 mg | Single dose | 608 ± 204 mg | 2 weeks | —         | —         |
| Fawrat 2014              | n = 290 F         | Transplant recipients Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Grote 2009               | n = 60 (n = 53 F)  | Transplant recipients Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 2 weeks | —         | —         |
| Gybel-Brask 2018         | n = 107 F         | Transplant recipients Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Jankowska 2021           | n = 1058 (n = 477 F) | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Johansson 2015           | n = 8 F           | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Keller 2020              | n = 405 (n = 187 F) | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Krayer 2021              | n = 75 (n = 24 F)  | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Krayenbuehl 2011         | n = 48 (n = 14 F)  | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Martens 2021             | n = 75 (n = 24 F)  | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Okonkwo 2014             | n = 35 (n = 10 F)  | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Santner 2020             | n = 48 (n = 14 F)  | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Song 2021                | n = 204 (n = 123 F) | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Trenkwalder 2017         | n = 110 (n = 90 F) | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Van Veekhuizen 2017      | n = 172 (n = 43 F) | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Wong 2016                | n = 35 (n = 10 F)  | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |
| Woods 2014               | n = 14 (n = 8 F)   | Pre-menopausal women Ferritin < 15 or < 30 μg/L | FCM 1000 mg | Single dose | 1000 mg | 4 weeks | —         | —         |

Abbreviations: F, females; FCM, ferric carboxymaltose; TSAT, transferrin saturation.
extracting data. Studies frequently reported outcomes in differing ways (i.e., absolute values at follow-up vs. change from baseline), which consequently saw them excluded from the analysis despite considerable efforts being made to contact the authors and resolve these difficulties.

In conclusion, the appropriateness of intravenous iron therapy for the treatment of non-anaemic iron deficiency remains uncertain. The present study demonstrated that intravenous iron therapy is associated with reduced fatigue scores; however, the effects on physical function remain poorly defined due to low-quality evidence. Overall, there is a need for more RCTs at a low risk of bias, which are powered to measure clinically important differences in physical function. Despite affirming empirical evidence, intravenous iron therapy remains a common clinical practice in this demographic, giving additional impetus to future research efforts.

Acknowledgements

The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.29

---

**Figure 5** Intravenous iron versus placebo forest plots. Squares indicate study-specific mean difference (MD) or standardized mean difference (SMD) estimates; horizontal lines indicate the 95% confidence interval (CI); diamonds indicate the pooled MD or pooled SMD with their 95% CIs. (A) Peak oxygen consumption (MD). (B) Physical function as defined by trial authors (SMD). (C) Fatigue at the end of follow-up (SMD). (D) Quality of life at the end of follow-up (SMD).
Figure 6 Intravenous iron versus placebo forest plots. Squares indicate study-specific mean difference (MD) or standardized mean difference (SMD) estimates or pooled risk ratios (RRs) or pooled risk differences (RDs) estimates; horizontal lines indicate the 95% confidence interval (CI); diamonds indicate the pooled MD or pooled SMD with their 95% CIs. (A) Haemoglobin concentration at the end of follow-up (MD). (B) Ferritin concentration at the end of follow-up (MD). (C) Mild adverse events at the end of follow-up. (D) Serious adverse events at the end of follow-up (RDs).
Conflicts of interest

Lachlan F. Miles is the coordinating principal investigator on a currently running prospective study that has received funds from Vifor Pharma as part of a matched funding arrangement with the Victorian Government. Toby Richards has received grants, personal fees and non-financial support from Pharmacosmos and Vifor Pharma. He has also received speaker’s honoraria from Medtronic. Professor Richards is also a regular speaker at national and international conferences on anaemia, blood transfusion, wound healing and vascular diseases for which he has received expenses for travel, accommodation and sundries. He has worked with several agencies promoting meetings or healthcare, is a director of The Iron Clinic Ltd and director of VeinCare London Ltd and is also the Vascular Lead for 18-week Wait Ltd. Both Katerina Cabolis and Cory Dugan have no conflicts of interest to declare.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

References

1. Kassebaum NJ. The global burden of anemia. Hematology/Oncology Clinics 2016;30:247–308.

2. Edgerton VR, Gardner GW, Ohira Y, Gunawardena KA, Senewiratne B. Iron-deficiency anaemia and its effect on worker productivity and activity patterns. Br Med J 1979;2:1546–1549.

3. Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131:6765–6905.

4. Pasricha S-R, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. The Lancet 2020.

5. Dugan C, Scott C, Abeyesri S, Baikady RR, Richards T. The need to screen for anaemia in exercising women. Medicine 2021;100:e27271.

6. Abeyesri S, Dugan C, Raobailardy K, Richards T, Scott C. The need to screen for anaemia in female populations. J Sci Med Sport 2021;24:530–531.

7. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001;33:940–959.

8. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences 2014;19:164–174.

9. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131:5868–5805.

10. Pasricha S-R, McHugh K, Drakesmith H. Regulation of hepcidin by erythropoiesis: the story so far. Annu Rev Nutr 2016;36:417–434.

11. Youdim MB, Ben-Shachar D, Yehuda S. Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. Am J Clin Nutr 1989;50:607–617.

12. Harber VJ, Petersen SR, Chilibeck PD. Thyroid hormone concentrations and muscle metabolism in amenorrheic and eumenorrheic athletes. Can J Appl Physiol 1998;23:293–306.

13. Stugiewicz M, Tkaczyzyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail 2016;18:762–773.

14. WHO. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. World Health Organization; 2011.

15. Boulton FE. The myoglobin content of human skeletal muscle. Br J Haematol 1973;25:281.

16. van Dronkelaar C, van Velzen A, Abdelrazek M, van der Steen A, Weijs PJM, Tieland M. Minerals and sarcopenia: the role of calcium, iron, magnesium, phosphorus, potassium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: a systematic review. J Am Med Dir Assoc 2018;19:6–11.

17. Dziegala M, Josiak K, Kasztura M, Kobak K, van Haehling S, Banasiak W, et al. Iron deficiency as energetic insult to skeletal muscle in chronic diseases. J Cachexia Sarcopenia Muscle 2018;9:802–815.

18. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled study. PloS one 2014;9:e94217.

19. Woods A, Garvican-Lewis LA, Saunders PU, Lovell G, Hughes D, Fazakerley R, et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PloS one 2014;9:e108042.

20. Garvican LA, Lobigs L, Telford R, Fallon K, Gore CJ. Haemoglobin mass in an anaemic female endurance runner before and after iron supplementation. Int J Sports Physiol Perform 2011;6:137–140.

21. Miles LF, Litton E, Imberger G, Story D, Cochrane Injuries Group. Intravenous iron therapy for non-anaemic, iron-deficient adults. Cochrane Database Syst Rev 2019;12.

22. Garvican LA, Saunders PU, Cardoso T, Macdougallic IC, Lobigs LM, Fazakerley R, et al. Intravenous iron supplementation in distance runners with low or suboptimal ferritin. Med Sci Sports Exerc 2014;46:376–385.

23. Burden RJ, Pollock N, Whyte GP, Richards T, Moore B, Busbridge M, et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Med Sci Sports Exerc 2015;47:1399–1407.

24. Pasricha SR, Low M, Thompson J, Farrell A, de-Regil LM. Iron supplementation benefits physical performance in women of reproductive age: a systematic review and meta-analysis. J Nutr 2014;144:906–914.

25. Shand AW, Bell J, Henry A, Grzeskowiak LE, Kidson- Gerber G, Pearson S, et al. Rapid increase in intravenous iron therapy for women of reproductive age in Australia. Medical Journal of Australia 2020;213:85–88.

26. Richards T, Breymann C, Brookes MJ, Lindgren S, Macdougallic IC, McMahon LP, et al. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Ann Med 2021;53:274–285.

27. Bhandari S, Pereira D, Chappell H, Drakesmith H. Intravenous iron: from basic science to clinical practice. Pharmaceuticals 2018;11:82.

28. Muñoz M, Gómez-Ramírez S, Kozek-Langenecker S. Pre-operative haematological assessment in patients scheduled for major surgery. Anaesthesia 2016;71:19–28.

29. Dugan C, MacLean B, Cabolis K, Abeyesri S, Khong A, Sajic M, et al. The misgony of iron deficiency. Anaesthesia 2021;76:56–62.

30. Higgins J, Wells G. Cochrane Handbook for Systematic Reviews of Interventions. 2011.

31. Beck-da-Silva L, Fiadri D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013;168:3439–3442.

Journal of Cachexia, Sarcopenia and Muscle 2022; 13: 2637–2649
DOI: 10.1002/jcsm.13114
Intravenous iron therapy for adults with non-anaemic iron deficiency

32. RevMan R. The Nordic Cochrane Centre, the Cochrane Collaboration. 2014, Book [computer program]. version.
33. Martens P, Dupont M, Dauw J, Nijst P, Herbots L, Dendale P, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodeling following cardiac resynchronization therapy—the IRON-CRT trial. *Euro Heart J* 2021;42:4905–4914.
34. Keller P, von Känel R, Hincapié CA, da Costa BR, Jüni P, Erlanger TE, et al. The effects of intravenous iron supplementation on fatigue and general health in non-anaemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. *Sci Rep* 2020;10:14219.
35. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. *New England Journal of Medicine* 2009;361:2436–2448.
36. Assessing risk of bias in a randomized trial. In *Cochrane Handbook for Systematic Reviews of Interventions*. 2019. p 205–228.
37. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Schramm H, et al. Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In *Cochrane Handbook for Systematic Reviews of Interventions*. 2019. p 375–402.
38. Bhanderi S, Algar V, Lamplugh A, Macdougall I, Kalra PA. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Desferal®) in iron deficient but not anaemic patients with chronic kidney disease on functional status. *BMC Nephrol* 2021;22:115.
39. Boomershine CS, Koch TA, Morris D. A blinded, randomized, placebo-controlled study to investigate the efficacy and safety of ferric carboxymaltose in iron-deficient patients with fibromyalgia. *Rheumatology and Therapy* 2018;5:271–281.
40. Brautaset Englund KV, Østby CM, Rolid K, Gude E, Andreassen AK, Gulseth L, et al. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (Ironic): a randomized clinical trial. *J Heart Lung Transplant* 2021;40:359–367.
41. Charles-Edwards G, Amaral N, Sleighth A, Ayis S, Catbog N, McDonagh T, et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. *Circulation* 2019;139:2386–2398.
42. Grote L, Leissner L, Hedner J, Ulffberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. *Mov Disord* 2009;24:1445–1452.
43. Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. *Transfusion* 2018;58:974–981.
44. Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. *Euro Heart J* 2021;42:3011–3020.
45. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). *Vox Sang* 2015;109:257–266.
46. Krähenbühl PA, Battugay E, Breyman C, Furrer J, Schultness G. Intravenous iron for the treatment of fatigue in nonanaemic, premenopausal women with low serum ferritin concentration. *Blood* 2011;118:3222–3227.
47. Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanaemic patients with symptomatic chronic heart failure and iron deficiency. FERRIC-HF: a randomized, controlled, observer-blinded trial. *J Am Coll Cardiol* 2008;51:103–112.
48. Santer P, McGahey A, Frise MC, Petousi N, Talbot NP, Baskerville R, et al. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial. *BMJ Open Respir Res* 2020;7:e000577.
49. Song JW, Soh S, Shim JK, Lee S, Lee SH, Kim HB, et al. Effect of perioperative intravenous iron supplementation for complex cardiac surgery on transfusion requirements: a randomized, double-blinded placebo-controlled trial. *Ann Surg* 2021;275:232–239.
50. Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A, et al. Ferric carboxymaltose in patients with restless legs syndrome and nonanaemic iron deficiency: a randomized trial. *Mov Disord* 2017;32:1478–1482.
51. van Veldhuisen D, Ponikowski P, van der Meer P, Metra M, Böh M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. *Circulation* 2017;136:1374–1383.
52. Wong C, Ng A, Lau J, Kritikarides L, Sindone A. Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. *Heart Lung Circ* 2016;25:S107.
53. Burden RJ, Morton K, Richards T, Whyte GP, Pedlar CR. Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis. *Br J Sports Med* 2015;49:1389–1397.
54. Rubeor A, Gooija C, Manning J, White J. Does iron supplementation improve performance in iron-deficient non-anaemic athletes? *Sports Health* 2018;10:400–405.
55. Peeling P, Blee T, Goodman C, Dawson B, Claydon G, Beilby J, et al. Effect of iron injections on aerobic-exercise performance of iron-depleted female athletes. *Int J Sport Nutr Exerc Metab* 2007;17:221–231.
56. Houston BL, Hurrie D, Graham J, Perija B, Rimmer E, Rabbani R, et al. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. *BMJ Open* 2018;8:e019240.
57. Frise MC, Holdsworth DA, Johnson AW, Chung VJ, Curtis MK, Cox PJ, et al. Abnormal whole-body energy metabolism in iron-deficient humans despite preserved skeletal muscle oxidative phosphorylation. *Sci Rep* 2022;12:998.
58. Beattie WS, Lalu M, Bocock M, Feng S, Wijesundera DN, Nagele P, et al. Systematic review and consensus definitions for the Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes. *Br J Anaesth* 2021;126:56–66.
59. von Haelbling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. *J Cachexia Sarcopenia Muscle* 2021;12:2259–2261.